



PRESS RELEASE – 4 JUNE 2026

## moveUP and Cascador Health Merge to Build a Data-Driven Digital Health Powerhouse

**Brussels / Ghent, 3 June 2026** – Cascador Health and moveUP today announce the completion of their merger, creating critical mass by combining two digital health specialists. The combined company already works with 8 of the top 10 global pharmaceutical companies, operates internationally, and supports more than 100,000 patients globally across its solutions. Customers include AstraZeneca, Sanofi, UCB and ArgenX. The joint company will go by the name of Cascador/moveUP and can rely on a multidisciplinary staff of 35 specialists based in Brussels and Ghent. Investors from both companies have invested €6 million in fresh capital alongside the merger – a signal of confidence in the strategy and recognition of the market position the companies have established in therapeutic areas such as epilepsy, orthopedics, respiratory immunology and rare diseases. The shared mission: to unlock the value of health data to help deliver the right treatment to the right patient at the right time.

*“This merger reflects my strong belief that critical mass is what it takes to become a successful digital health player. It is the only way to earn the trust of life sciences companies, build a sustainable business, and ultimately improve as many patients’ lives as possible. I am excited that moveUP shared this vision with Cascador Health. Combined, we have the expertise and the platform to scale further in the disease areas we are already active in, unlock new disease areas and geographies, and pursue international M&A opportunities to consolidate this fragmented market. The deal is backed by significant investment from both our existing investors and the management team – a clear signal of shared conviction in our approach and in this market.”*

– Philip Taillieu, Co-Founder & CEO

### A structurally different proposition

Digital health and real-world data have the power to transform healthcare from a discipline of averages into one of precision – where every patient's journey generates the insight that makes the next patient's care better. Most digital health vendors address only one stage of the patient journey, leaving life sciences companies to assemble a patchwork of disconnected tools – with no continuity of data, no unified patient view, and significant integration overhead for healthcare providers. Cascador/moveUP eliminates that fragmentation. With capabilities spanning the full therapy lifecycle, from pre-market R&D and clinical trials to routine care, the combined company offers something structurally different: a single partner, a coherent data architecture, and a single accountable team across the full therapy lifecycle.

*“For too long, the data generated by patients in real clinical settings has been underused – locked in silos, poorly structured, or simply never collected in a way that supports decisions. The right treatment to the right patient at the right time is not just a clinical aspiration; it is a data*



*opportunity. Cascador/moveUP gives us the reach, the regulatory credibility, and the clinical relationships to finally unlock that data to have impact at scale.”*

– Ward Servaes, Co-Founder & Chief Product Officer

## **An end-to-end offering across the product lifecycle**

The combined company's four capabilities map directly to the therapy lifecycle:

- Clinical Trial Solutions – market leader for eCOA/eDiary in epilepsy clinical trials and preferred partner of leading Clinical Research Organizations.
- Real-world data and multi-sponsor registries for reimbursement, health technology assessment, and post-approval evidence, with a.o. programs having supported reimbursement of innovative drugs in COPD, CRS, and CLL.
- Patient support programs for longitudinal engagement and adherence, deployed in multiple countries for areas like rare neurological diseases, musculoskeletal and innovative obesity medication.
- Remote patient monitoring for outcome optimization, deployed internationally with renowned academic and private care institutions.

## **Why now**

Digital health is entering a consolidation phase: payers demand real-world outcomes to underpin value-based reimbursement, regulators require post-market evidence as a condition of market access, and life sciences companies increasingly seek partners that can support the full patient journey rather than fragments of it. The combined entity is purpose-built for that environment. Common technologies and datasets can be leveraged across the full product lifecycle, creating important efficiency and cost benefits.

Both organizations enter the combination from a position of operational maturity, with complementary client bases, a validated platform, and mutually reinforcing offerings. The combined entity maintains EU MDR Class IIa products, ICH GCP compliance, and ISO 13485 and ISO 27001 certifications – the compliance and data governance credentials that life sciences customers require. For existing customers, the merger means continuity, expanded capability, and a stronger partner.

## **Leadership and investor backing**

The combined leadership team brings together executives from both organizations: Philip Taillieu as CEO, Charles-Eric Winandy as Chief Revenue Officer, Jonathan Schreiber as Chief Operating Officer, Ward Servaes as Chief Product Officer, Sven Van Segbroeck as Chief Technology Officer, and Ludo Ooms as Chief Financial Officer.

The €6 million capital investment is backed by leading Belgian and European health tech and venture investors from both companies, including Qbic, Ethias Ventures, White Fund, Karista,



CAREvolution, and Volta Ventures, alongside other existing shareholders and the management team, who continue to support the group's European expansion and consolidation strategy.

### **About the combined company**

The combined company is a Belgian-headquartered digital health organization providing regulated remote patient monitoring, eCOA/eDiary, patient support, real-world data, registries, and evidence-generation solutions to life sciences companies, medtech organizations, payers, and healthcare providers. With a deliberate focus on designated therapeutic areas, the combined company brings deep clinical networks and domain expertise that generic digital health platforms cannot replicate. The combined company serves global customers and markets, with a focus on European expansion. Its mission is to unlock the value of patient data to help deliver the right treatment to the right patient at the right time.

Website: [www.moveup.care](http://www.moveup.care) / [www.cascador.health](http://www.cascador.health) | Media contact: [Philip@cascador.health](mailto:Philip@cascador.health) +32 476 984 009